%0 Journal Article
%T A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans.
%A Mortimore AM
%A Barsoum R
%A Lambie D
%A McMeniman E
%J Australas J Dermatol
%V 0
%N 0
%D Jul 2021 27
%M 34314029
%F 2.481
%R 10.1111/ajd.13674
%X Treatment for telangiectasia macularis eruptiva perstans (TMEP) is often challenging due to lack of an established first-line therapy and as such is primarily focused on symptomatic relief. Omalizumab shows promise as a potential therapy for mast cell disorders; however, its efficacy in TMEP is yet to be established. This case describes a 72-year-old woman with chronic refractory TMEP achieving symptomatic remission within 4 months of commencing omalizumab therapy.